An Israeli company which is developed new antimicrobial peptides has won €10.8 million in European Union funding to conduct early clinical studies of a product directed against infections caused by Gram-negative bacteria. Omnix Medical Ltd of Jerusalem has developed its technology by studying how insects use their innate immune systems to kill bacteria – an evolutionary mechanism that goes back millions of years.
